DK3129374T3 - (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER - Google Patents

(5,6-dihydro) pyrimido [4,5-e] INDOLIZINER Download PDF

Info

Publication number
DK3129374T3
DK3129374T3 DK15712912.3T DK15712912T DK3129374T3 DK 3129374 T3 DK3129374 T3 DK 3129374T3 DK 15712912 T DK15712912 T DK 15712912T DK 3129374 T3 DK3129374 T3 DK 3129374T3
Authority
DK
Denmark
Prior art keywords
carboxamide
indolizine
dihydropyrimido
anilino
alkyl
Prior art date
Application number
DK15712912.3T
Other languages
Danish (da)
English (en)
Inventor
Man Adrianus Petrus Antonius De
Rogier Christian Buijsman
Jan Gerard Sterrenburg
Joost Cornelis Marinus Uitdehaag
Wit Joeri Johannes Petrus De
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Application granted granted Critical
Publication of DK3129374T3 publication Critical patent/DK3129374T3/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15712912.3T 2014-04-07 2015-03-30 (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER DK3129374T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (1)

Publication Number Publication Date
DK3129374T3 true DK3129374T3 (en) 2019-04-08

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15712912.3T DK3129374T3 (en) 2014-04-07 2015-03-30 (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER

Country Status (16)

Country Link
US (3) USRE50082E1 (enExample)
EP (1) EP3129374B1 (enExample)
JP (1) JP6518690B2 (enExample)
KR (1) KR102432420B1 (enExample)
CN (1) CN106132963B (enExample)
AU (1) AU2015243694B2 (enExample)
BR (1) BR112016022342B1 (enExample)
CA (1) CA2944610C (enExample)
DK (1) DK3129374T3 (enExample)
ES (1) ES2716165T3 (enExample)
HU (1) HUE043108T2 (enExample)
MX (1) MX368767B (enExample)
PL (1) PL3129374T3 (enExample)
PT (1) PT3129374T (enExample)
RU (1) RU2692479C2 (enExample)
WO (1) WO2015155042A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines
WO2016166255A1 (en) 2015-04-17 2016-10-20 Netherlands Translational Research Center B.V. Prognostic biomarkers for ttk inhibitor chemotherapy
EP3416964B1 (en) * 2016-02-19 2020-12-16 Phoenix Molecular Designs 6-oxo-n-(1-(benzyl)-1h-pyrazol-4-yl)-6,7,8,9- tetrahydropyrido[3',2':4,5]pyrrolo[1,2-a]pyrazine-2-carboxamide derivatives as p90 ribosomal s6 kinase (rsk) inhibitors for treating cancer
EA202092441A1 (ru) 2016-06-07 2021-05-21 Джакобио Фармасьютикалс Ко., Лтд. Новые гетероциклические производные, применимые в качестве ингибиторов shp2
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
TWI664175B (zh) 2017-03-23 2019-07-01 大陸商北京加科思新藥研發有限公司 用於作為shp2抑制劑之新穎雜環衍生物
WO2020063760A1 (en) 2018-09-26 2020-04-02 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
EP3924352A4 (en) 2019-02-11 2022-11-16 Phoenix Molecular Designs CRYSTALLINE FORMS OF AN RSK INHIBITOR
MX2024007451A (es) * 2021-12-15 2024-07-09 Sillajen Inc Metodos de tratamiento de enfermedades neoplasicas.
MX2024007450A (es) * 2021-12-15 2024-07-04 Sillajen Inc Combinaciones farmaceuticas para utilizarse en el tratamiento de enfermedades neoplasicas.
KR20240096905A (ko) * 2021-12-15 2024-06-26 신라젠(주) 변형된 베타-사이클로덱스트린을 포함하는 약제학적 조성물
MX2024010802A (es) * 2022-03-04 2024-09-11 Sillajen Inc Combinaciones farmaceuticas para uso en el tratamiento de enfermedades neoplasicas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160915A0 (en) * 2001-09-19 2004-08-31 Aventis Pharma Sa Indolizines inhibiting kinase proteins
DK1636236T3 (da) 2003-05-22 2013-12-09 Nerviano Medical Sciences Srl Pyrazolo-quinazolin-derivater, en fremgangsmåde til fremstilling deraf, og deres anvendelse som kinase-inhibitorer
US8207180B2 (en) 2006-11-28 2012-06-26 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
JP5542133B2 (ja) * 2008-06-26 2014-07-09 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ ピラゾロ−キナゾリン
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
ES2660146T3 (es) 2009-04-29 2018-03-21 Nerviano Medical Sciences S.R.L. Sales del inhibidor de cdk
JP5851990B2 (ja) 2009-07-29 2016-02-03 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ Plk阻害剤の塩
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
WO2012080229A1 (en) 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
BR112013018515B1 (pt) * 2011-01-26 2021-06-29 Nerviano Medical Sciences S.R.I Derivados de pirrol tricíclico, processo para sua preparação e seu uso como inibidores da quinase
AU2014302710B2 (en) 2013-06-24 2018-10-04 Merck Patent Gmbh Imidazole compounds as modulators of FSHR and uses thereof
CA2944610C (en) * 2014-04-07 2024-01-09 Netherlands Translational Research Center B.V. (5,6-dihydro)pyrimido[4,5-e]indolizines

Also Published As

Publication number Publication date
CN106132963A (zh) 2016-11-16
KR102432420B1 (ko) 2022-08-17
MX2016012997A (es) 2016-12-07
USRE48974E1 (en) 2022-03-15
US9856258B2 (en) 2018-01-02
EP3129374B1 (en) 2018-12-19
RU2692479C2 (ru) 2019-06-25
HUE043108T2 (hu) 2019-07-29
EP3129374A1 (en) 2017-02-15
JP2017510595A (ja) 2017-04-13
BR112016022342B1 (pt) 2022-10-04
ES2716165T3 (es) 2019-06-10
USRE50082E1 (en) 2024-08-20
RU2016141405A (ru) 2018-05-07
CN106132963B (zh) 2019-08-06
MX368767B (es) 2019-10-15
AU2015243694A1 (en) 2016-11-03
AU2015243694B2 (en) 2019-01-17
CA2944610C (en) 2024-01-09
PT3129374T (pt) 2019-03-25
RU2016141405A3 (enExample) 2018-10-02
CA2944610A1 (en) 2015-10-15
KR20170013866A (ko) 2017-02-07
BR112016022342A2 (pt) 2017-08-15
PL3129374T3 (pl) 2019-07-31
BR112016022342A8 (pt) 2021-07-20
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
JP6518690B2 (ja) 2019-05-22

Similar Documents

Publication Publication Date Title
DK3129374T3 (en) (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
JP6726677B2 (ja) 抗がん剤としての置換2−h−ピラゾール誘導体
AU2016352813B2 (en) Novel pyrazolo pyrimidine derivatives
EP3559000B1 (en) Benzimidazole derivatives, preparation methods and uses theirof
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
AU2015407300B2 (en) 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CA2791166C (en) Pyrazolopyrimidine compounds and their use as pde10 inhibitors
AU2020255100A1 (en) N-heteroaromatic amide derivatives for treatment of cancer
AU2013344049A1 (en) ALK kinase inhibitors
CN117693503A (zh) 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5,6-二氢)嘧啶并[4,5-e]吲嗪
CN118580220A (zh) 一类细胞周期依赖性蛋白激酶12/13的降解剂,及其制备方法、药物组合物和应用
EA041747B1 (ru) Ингибиторы g12c kras, содержащая их фармацевтическая композиция и использующий их способ лечения рака